In the first part of our study, we analyzed sTIL, scored according to standard guidelines13, and multiple markers (CD3, CD4, CD8, CD68, CD73, PD-1, PD-L1, FOXP3, and Ki67) by immunohistochemistry (IHC) on formalin-fixed paraffin-embedded samples from tumor resection specimens of 163 patients with HR-negative stage 2–3 BC. This evidence concerns the gene CD4 and breast cancer.